Penn’s Innovation in Process Science combines with CBM manufacturing capability to develop large-scale gene therapy manufacturing capacity, testing, and analytics
A New York Times feature on the history, research, challenges, and timeline to make the COVID-19 mRNA vaccines.
The Journal of Precision Medicine highlighted Penn spinout Cogwear’s novel technology for behavioral health applications.
Moderna will collaborate with Penn spinout Carisma Therapeutics to discover, develop and commercialize in-vivo engineered chimeric antigen receptor monocyte therapeutics for the treatment of cancer.
Without the mRNA technology foundation laid by Karikó and Weissman, the Pfizer/BioNTech and Moderna vaccines being deployed across the world would not exist.
Technology used in mRNA COVID vaccines offers hope for treatment of millions with heart disease, study suggests
Combining technologies that proved hugely success against cancer and in COVID-19 vaccines, researchers at Penn have shown they can effectively treat a leading cause of heart disease.
The researchers, whose work is published in Science, demonstrated the new approach with an mRNA preparation that reprograms T cells—a powerful type of immune cell—to attack heart fibroblast cells.
These leaders made changes to workplace communication, collaboration and their personal lives.
She was described as being one of the 50 visionaries whose career-long actions have had far-reaching impact.
iECURE announced that it has entered into an exclusive agreement with Penn to develop next-generation lipid nanoparticles (LNP) for liver gene editing applications.